Teligent — IGI Laboratories — 25th Annual Roth Conference 2013
14 slides from Teligent's conference presentation, Mar 20, 2013
Slide 1: 25th Annual Roth Conference
Exhibit 99.1 25" Annual Roth Conference March 20, 2013 IGI Laboratories, Inc. Jason Grenfell-Gardner President and CEO Gian LABORATORIES
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by IGI Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and i
Slide 3: IGI Today
IG! Today Our mission is to be a leading player in the generic topical prescription drug market. Our Two Platforms for Growth: * Generic pharmaceuticals ¢ Formulation and manufacturing contract services
Slide 4: Generic Pharmaceuticals
Generic Pharmaceuticals = Organic ANDA pipeline, 9 applications pending at FDA In-House R&D = Expect to submit 6 ANDAs per year = Appointed Dr. Ken Miller SVP of R&D in December 2012 = Partnership with Medimetriks executed in 2011 Authorized . = IGI named AG distributor for certain products Generics
Slide 5: Contract Services
Contract Services = Product and formulation development for third parties, often resulting in a continuing manufacturing relationship Formulations = Developed more than 30 formulations in the past 2 years = Develop products for ANDAs, OTC, 510k, and cosmetics = Revenue more than doubled from 2011 to
Slide 6: Our IGI Products
Our IGI Products Authorized Generic IGI Products currently available: = Fluocinolone acetonide topical solution = Fluocinolone acetonide ointment, 15g and 60g = Fluocinolone acetonide cream, 15g and 60g Econozale nitrate cream 1% will be manufactured and distributed by IGI for IGI later this year, s
Slide 7: IGI Today
IG! Today IGI operates an FDA approved facility which passed its first pre- approval inspection in February 2012 with zero 483 observations =" Our facility has the capability to produce creams, ointments, lotions, gels, solutions, and suspensions = Since September of 2010, we filed our first 9 ANDAs
Slide 8: The Generic Topical Market
Salesin USS Mt The Generic Topical Market 8 8 8 8 500 ° GENERIC [BRANDED GENERIC Source: IMS Healthdara, MATJune : | BRAND MAT 6/2010 smMAT 6/2031 Mar 6/2012 = Addressable US topical market is $9 bn, of which generics make up $2.5 bn = The generic space has grown rapidly, a CAGR of 43% over three ye
Slide 9: Industry Consolidation
Industry Consolidation omnes Greenstone 125 Perigo 19% Fougers 2% 23% Total Market: $1.6 Total Market: $2.5 Source: IMS Health data, MATJune 2012 * The top four companies control 76% of the generic topical market by value * Over the past three years, some consolidation has happened through Sun’s acq
Slide 10: Less Competitive Niche
Less Competitive Niche Specific barriers to entry: = Topicals require specialized skills in formulation, bioequivalance management, and regulatory approach = Proving bioequivalence for many topicals is challenging, time consuming, and costly, often requiring in vivo clinical studies = Requires dedic
Slide 11: Topical Bio-Equivalence
Topical Bio-Equivalence = Topical Solutions Bio-Waivers = “Grandfathered” products = No costs for outside bioequivalence studies = Mostly required for corticosteroids Vasoconstriction ‘ = Studies can range typically from $100 - $350K Studies = Comparative clinical trials against the innovator drug f
Slide 12: Our Vision
Our Vision IGI seeks to become a top 5 companyin the topical space in the next 5 years through: C1) Growing our organic ANDA pipeline and executing our launch plan @ *tverv seeking business development opportunities for product acquisitions and partnering possibilities C3 Developing innovative produ
Slide 13: Financial Highlights
Financial Highlights = Historically, revenue from our contract manufacturing and formulations business has increased 40% from 2010 to 2012 = IGI label launched in December 2012, so historical financials do not include meaningful IGI revenue. = Revenue from pharmaceutical customers increased to almos
Slide 14: Accelerating Growth
Accelerating Growth = Expand internal R&D team under leadership of Dr. Miller Accelerating = Existing and identified molecules with an addressable market R&D Efforts of over $500 m which could be pulled forward into 2015 and 2016 approval horizon = Ability to take on products that have more involved